The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: A systematic review and meta-analysis

npj Schizophrenia

Volumn 4, Issue 1, 2018, Pages

  De Boer, Janna ^a   Prikken, Merel ^a   Lei, Wan U ^a   Begemann, Marieke ^a   Sommer, Iris ^b,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE;

ARTICLE; COGNITION; DEPRESSION; DEPRESSION ANXIETY STRESS SCALE; DISEASE SEVERITY; DRUG EFFECT; DSM-III; DSM-III-R; DSM-IV-TR; FEMALE; HUMAN; ICD-10; ICD-9; MALE; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA SPECTRUM DISORDER; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 85048019910     PISSN: None     EISSN: 2334265X     Source Type: Journal    
DOI: 10.1038/s41537-017-0043-3     Document Type: Article

References (43)

1. McGrath, J. et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2, 1 (2004).
2. Leung, A. & Chue, P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr. Scand. 101, 3-38 (2000).
3. Riecher-Rössler, A. & Häfner, H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr. Scand. Suppl. 102, 58-62 (2000).
4. Desai, P. R., Lawson, K. A., Barner, J. C. & Rascati, K. L. Identifying patient characteristics associated with high schizophrenia-related direct medical costs in community-dwelling patients. J. Manag. Care Pharm. 19, 468-477 (2013).
5. Grigoriadis, S. & Seeman, M. V. The role of estrogen in schizophrenia: Implications for schizophrenia practice guidelines for women. Can. J. Psychiatry 47, 437-442 (2002).
6. Bergemann, N., Parzer, P., Runnebaum, B., Resch, F. & Mundt, C. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol. Med. 37, 1427-1436 (2007).
7. Hoff, A. L. et al. Association of estrogen levels with neuropsychological performance in women with schizophrenia. Am. J. Psychiatry 158, 1134-1139 (2001).
8. Begemann, M. J. H., Dekker, C. F., van Lunenburg, M. & Sommer, I. E. Estrogen augmentation in schizophrenia: A quantitative review of current evidence. Schizophr. Res. 141, 179-184 (2012).
9. Heringa, S. M., Begemann, M. J. H., Goverde, A. J. & Sommer, I. E. C. Sex hormones and oxytocin augmentation strategies in schizophrenia: a quantitative review. Schizophr. Res. 168, 603-613 (2015).
10. Wang, Q., Dong, X., Wang, Y. & Li, X. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a meta-analysis of randomized controlled trials. Arch. Women's Ment. Health, https://doi.org/10.1007/s00737-017-0773-2 (2017).
11. Dhandapani, A., Narayanaswamy, J. C. & Venkatasubramanian, G. Adjuvant raloxifene treatment for negative symptoms of schizophrenia. Asian J. Psychiatr. 6, 254-255 (2013).
12. Grigg, J., Worsley, R. & Kulkarni, J. Raloxifene for schizophrenia and symptoms of hyperprolactinaemia? Aust. New Zeal. J. Psychiatry 4867416670014 (2016).
13. Huerta-Ramos, E., Ochoa, S., Roca, M., Miquel, E. & Usall, J. The effect of raloxifene on symptoms and cognitive functioning in a postmenopausal schizophrenia patient: a case report. Arch. Women's Ment. Health 18, 259-261 (2015).
14. Kulkarni, J. et al. Hormone modulation: a novel therapeutic approach for women with severe mental illness. Aust. New Zeal. J. Psychiatry 42, 83-88 (2008).
15. Sharma, E. et al. Beneficial effects of add-on raloxifene in schizophrenia A case report. Arch. Women's Ment. Health 15, 147-148 (2012).
16. Shivakumar, V. & Venkatasubramanian, G. Successful use of adjuvant raloxifene treatment in clozapine-resistant schizophrenia. Indian J. Psychiatry 54, 394 (2012).
17. Tharoor, H. & Goyal, A. Raloxifene trial in postmenopausal woman with treatment-resistant schizophrenia. Arch. Women's Ment. Health 18, 741-742 (2015).
18. Wong, J., Seeman, M. V. & Shapiro, H. Raloxifene in postmenopausal women with psychosis: preliminary findings. Am. J. Geriatr. Psychiatry 11, 697-698 (2003).
19. Kulkarni, J. et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 35, 1142-1147 (2010).
20. Kulkarni, J. et al. Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: a randomized clinical trial. JAMA Psychiatry 73, 947-954 (2016).
21. Kianimehr, G. et al. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. Daru 22, 55 (2014).
22. Khodaie-Ardakani, M. -R. et al. A placebo-controlled study of raloxifene added to risperidone in men with chronic schizophrenia. Acta Med. Iran. 53, 337-345 (2015).
23. Huerta-Ramos, E. et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur. Neuropsychopharmacol. 24, 223-231 (2014).
24. Usall, J. et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J. Clin. Psychiatry 72, 1552 (2011).
25. Usall, J. et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebocontrolled trial. Schizophr. Bull. 42, 309-317 (2015).
26. Weickert, T. W. et al. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol. Psychiatry 20, 685 (2015).
27. Weiser, M. et al. Raloxifene plus antipsychotics versus placebo plus antipsychotics in severely Ill decompensated postmenopausal women with schizophrenia or schizoaffective disorder: a randomized controlled trial. J. Clin. Psychiatry 78, e758 (2017).
28. Cauley, J. A. et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res. Treat. 65, 125-134 (2001).
29. Cummings, S. R. et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281, 2189-2197 (1999).
30. Ellis, A. J., Hendrick, V. M., Williams, R. & Komm, B. S. Selective estrogen receptor modulators in clinical practice: a safety overview. Expert. Opin. Drug. Saf. 14, 921-934 (2015).
31. Yaffe, K. et al. Cognitive function in postmenopausal women treated with raloxifene. N. Engl. J. Med. 344, 1207-1213 (2001).
32. Weickert, T. W. & Weickert, C. S. Raloxifene improves cognition in schizophrenia: spurious result or valid effect? Front. Psychiatry 8, 202 (2017).
33. Moher, D. et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 4, 1 (2015).
34. American Psychiatric Assocation. Diagnostic and Statistical Manual of Mental Disorders 4th edn (American Psychiatric Association, Washington, DC, 1994).
35. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th edn (American Psychiatric Pub, Arlington, VA, 2013).
36. Higgins, J. P. T. et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011).
37. Kay, S. R., Flszbein, A. & Opfer, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261 (1987).
38. Montgomery, S. A. & Asberg, M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382-389 (1979).
39. Lovibond, P. F. & Lovibond, S. H. The structure of negative emotional states: comparison of the depression anxiety stress scales (DASS) with the Beck Depression and Anxiety Inventories. Behav. Res. Ther. 33, 335-343 (1995).
40. Borenstein, M., Hedges, L., Higgins, J. & Rothstein, H. Comprehensive Meta-analysis Version 2. Vol. 104 (Biostat, Englewood, NJ, 2005).
41. Dunlap, W. P., Cortina, J. M., Vaslow, J. B. & Burke, M. J. Meta-analysis of experiments with matched groups or repeated measures designs. Psychological Methods 1, 170-177 (1996).
42. Higgins, E. T., Idson, L. C., Freitas, A. L., Spiegel, S. & Molden, D. C. Transfer of value from fit. J. Pers. Soc. Psychol. 84, 1140 (2003).
43. Cohen, J. Statistical Power Analysis for the Behavioral Sciences. Vol. 2 (Hilsdale, NJ Lawrence Earlbaum Assoc., 1988).